Verada.Health exists to make quality rehabilitation accessible — so every patient gets the right care, at the right intensity, when they need it. When that happens, patients recover. And patients who recover don't become claimants, don't churn, and don't create liability. We deliver this across MSK and neurological pathways, with sensor-validated assessment that makes clinical decisions defensible.
View Investment Terms →The same systemic failures cost the NHS billions in liability and cost private providers their competitive edge. What the public sector experiences as infrastructure collapse, the private sector experiences as commercial erosion. Here is how each crisis manifests across both MSK and neurological pathways.
This liability doesn't accumulate because of missing paperwork — it accumulates because patients aren't recovering. The clinical capability to change that exists. What's missing is a delivery partner that can make quality rehabilitation accessible at population scale, across care settings, for both MSK and neurological pathways.
Verada.Health is building the UK's first virtual rehabilitation clinic — a delivery partner that absorbs patient load from NHS trusts, private clinics, insurers, and employers. We exist to ensure every patient gets the right attention, at the right intensity, at the right time. The sensors make that possible. The platform makes it scalable. The outcome — patients who actually recover — is what eliminates claims, stops revenue leakage, and reduces provider burden.
The £60bn problem starts with one patient who didn't recover.
Every claim traces back to a failure because of atleast one of those five crises. Patients who wait too long, miss their treatment window, or receive subtherapeutic intensity don't recover. And unrecovered patients seek accountability.
Patients who get objective attention recover. Patients who recover don't sue.
Objective attention means sensor-validated assessment, verified treatment intensity, and continuous monitoring across settings. When patients get what they actually need — not what time constraints allow — they recover.
We deliver objective attention. Recovery follows. Claims don't.
Verada.Health is building a virtual rehabilitation clinic that absorbs demand providers can't meet alone — designed towards CQC-registration, deploying sensor-validated care across MSK and neuro pathways, at population scale.
Two pathways, two device families — both proven, both integrated into a single care delivery model.
Surface EMG and range-of-motion assessment for musculoskeletal conditions. Detects muscle activation patterns that camera-based systems cannot see.
Synchronized EEG-EMG biofeedback for stroke, TBI, and Parkinson's rehabilitation. Monitors brain-muscle coordination in real time.
The digital thread connecting hospital ward, clinic, and patient home. Creates the defensible audit trail for evidence-based discharge decisions and outcome-based commissioning.
Every capability creates documented evidence that strengthens clinical governance
What makes this difficult to replicate
Exclusive distribution rights for Startoon Labs' EMG/ROM technology in the UK market. Competitors cannot access this device without renegotiating directly with the manufacturer.
Preferred partner status with SynPhNe Pte Ltd for neurorehab deployment. First-mover relationship in a market with very few EEG-EMG biofeedback options.
No competitor offers both MSK and neurorehab from a single service model. This means one referral relationship, one contract, one data trail — for providers managing both patient populations.
We absorb patient load, not just license software. Designed to meet CQC registration standards — enabling direct NHS referrals and positioning as a qualified clinical partner, not a vendor.
The patient's recovery journey spans three distinct settings, but the data thread remains unbroken. This continuity is what bridges the 7-day cliff-edge and ensures therapeutic intensity is maintained from specialist ward to patient home.
Two sensor pathways converge into a single UK-hosted data infrastructure. Partner devices communicate through their native applications to central Verada servers deployed in the UK, with bidirectional connectivity to NHS systems and private EHR platforms.
Digital rehabilitation is no longer experimental. NHS virtual ward allocation has reached £150 million, approximately half of all Integrated Care Boards are now operating virtual wards, and published evidence shows £3.10 ROI per £1 invested in virtual care alongside 63% reduction in A&E presentations. The market is ready for sensor-validated solutions.
The digital rehabilitation market is crowded with camera-based solutions that cannot detect muscle activation. Verada is the only platform combining MSK and neurological pathways with objective EMG and EEG-EMG sensor validation, delivered through exclusive UK hardware partnerships.
| Capability | Verada | Doccla | SWORD | Flok | Hinge |
|---|---|---|---|---|---|
| MSK Pathway | ✓ | ✗ | ✓ | ✓ | ✓ |
| NeuroRehab Pathway | ✓ | ✗ | ✗ | ✗ | ✗ |
| EMG Sensor Validation | ✓ | ✗ | ✗ | ✗ | ✗ |
| Self-Referral Access | ✓ | ✗ | ✗ | ✓ | ✗ |
| Hardware Exclusivity | ✓ | N/A | ✗ | N/A | ✗ |
These aren't expensive medical gadgets. They're financial firewalls against macro-economic collapse. Here's how Verada addresses the three crises that threaten ICB solvency and insurer exposure.
300,000 patients waiting, not healing
£26bn annual MSK burden
Every day in queue = condition chronicises
Remote Triage & Monitoring
One clinician monitors 50 patients. Pheezee flags who needs escalation now vs who can safely continue home therapy.
Accelerates return-to-work
Reduces productivity loss and prevents condition progression to permanent disability
85,000 survivors missing neuroplasticity
£26bn lifetime neuro burden
Missed window = permanent care dependency
Window Expansion
SynPhNe starts brain-muscle retraining while patients wait for clinic slots. Captures recovery signals standard care misses.
Converts liability to recovery
10% return to independent living = billions saved in social care
Diagnostic error is the #1 cause of claims
£60bn NHS negligence liability
Subjective notes lose cases
Clinical Black Box
Automated, timestamped sensor records. Every anomaly flagged, every clinical response documented.
Defensible position
Objective evidence replaces "he said, she said" in tribunal
By deploying Verada, you establish a new gold standard for the Bolam Test. You replace subjective notes — which lose cases — with objective, timestamped evidence. You're not just healing patients; you're insuring the Trust against the most expensive categories of clinical error.
Verada operates as a B2B2C virtual care facility, generating revenue through a combination of per-episode payments, platform subscriptions, device leasing, and outcome-based commissioning. This diversified model reduces dependency on any single payer type while aligning incentives with clinical outcomes.
The go-to-market strategy prioritises private sector deployment to generate early revenue and clinical evidence, followed by NHS procurement once CQC registration and UK clinical data are established, with international expansion via existing investor and partner relationships.
Deploy with UK private physiotherapy clinics, corporate wellness programmes, and private medical insurers. Generate revenue, refine workflows, and build UK clinical evidence base. Complete CQC registration to enable clinical service delivery.
Target: 3–5 clinical sitesEngage Primary Care Networks and NHS stroke units with published UK clinical outcomes. Leverage virtual ward funding allocation and demonstrate capacity multiplication value proposition. Pursue NHS framework agreements and ICB contracts.
Target: 10–25 clinical sitesEnter US market via pre-seed investor network and SynPhNe Health Inc. subsidiary relationship. Leverage FDA-cleared device status for accelerated market entry. Explore EU markets with CE/UKCA pathway alignment.
Target: US market entryOur sensor hardware partners have already achieved regulatory clearance in major markets. Pheezee holds regulatory approval in India with over 200 clinical installations and 11,000 patients assessed. SynPhNe is FDA-cleared in the United States and approved in Singapore for stroke and TBI rehabilitation. For UK market entry, we are pursuing the standard MHRA clinical investigation pathway, the established route for international medical devices entering the British market.
Formal regulatory engagement with the Medicines and Healthcare products Regulatory Agency, initiating the UK clinical evidence generation process with approved international devices.
Care Quality Commission registration enables Verada.Health to deliver regulated clinical services in England, a prerequisite for NHS and insurer contracting.
REC approval authorises commencement of formal clinical investigation, enabling peer-reviewable UK outcomes data collection.
Peer-reviewed publication of UK clinical outcomes data, establishing evidence base for NHS procurement and insurance reimbursement discussions.
Submission for UK Conformity Assessed marking, the regulatory pathway to full UK market authorisation based on accumulated clinical evidence.
Our pre-revenue status reflects a deliberate regulatory pathway rather than execution failure. The 18-month runway is specifically sized for the pre-commercial evidence generation phase that medical device market entry requires. Partner devices are already proven safe and effective in international markets with thousands of patients assessed. Published UK clinical outcomes will create a significant competitive moat at commercial launch, as competitors would need to replicate the entire evidence generation process to match our regulatory position.
The financial model reflects a phased rollout beginning with private sector deployment, expanding to NHS contracting, and scaling through international market entry. EBITDA positive by Year 2 with accelerating margins as platform economics take effect.
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Clinical Sites | 5 | 25 | 80 | 200 | 400 |
| Patient Episodes | 2,500 | 15,000 | 60,000 | 180,000 | 400,000 |
| Revenue | £180K | £1.1M | £4.2M | £12M | £28M |
| EBITDA | (£95K) | £85K | £650K | £2.4M | £6.5M |
Total seed capital of £120,000 comprises the £100,000 pre-seed investment plus £20,000 founder contribution, providing an 18-month runway through the regulatory pathway and initial commercial deployment.
Verada.Health is led by a founder with 24 years spanning IT infrastructure, artificial intelligence, healthcare technology, and pharmaceutical regulatory affairs. This combination of technical depth and healthcare domain expertise is precisely what sensor-validated rehabilitation requires.
Dilip brings a rare combination of healthcare technology leadership and hands-on experience with the exact sensor platforms Verada will deploy. As Chief Growth Officer at Startoon Labs, he led the commercial expansion of Pheezee technology across clinical settings. His parallel work with SynPhNe on go-to-market strategy for the neurological pathway means he has deep operational knowledge of both hardware platforms, their clinical applications, and the regulatory landscape they operate within.
Verada.Health has secured £100,000 pre-seed investment from Shiva Physical Therapy LLC, a registered physiotherapy clinic and franchise owner in North Carolina, USA. This represents subject matter expert validation from a practicing clinician who has evaluated the technology and business model with professional expertise.
First-mover advantage in sensor-validated virtual rehabilitation. Dual-pathway architecture serving both MSK and neurological conditions from a single platform. Hardware exclusivity through negotiated UK licensing agreements. Subject matter expert validation through committed investment from a practicing clinician.